Staar Surgical (STAA)

The company designs, develops, manufactures, and sells both the lenses and the related delivery systems used by ophthalmic surgeons. STAAR’s revenue is heavily concentrated in ICL products, making adoption of implantable lens surgery the central driver of its business. Demand is influenced by surgeon training, patient awareness, regulatory approvals, reimbursement patterns, and consumer willingness to pay for elective vision correction.

STAAR operates in the global ophthalmology market and generates a significant majority of its sales outside the United States. This international mix gives the company exposure to large vision-correction markets, particularly where premium refractive procedures are growing, but it also brings currency, regulatory, and regional execution risks. Its competitive position depends on clinical outcomes, product quality, surgeon relationships, and the ability to expand the addressable patient population through new lens designs and approvals. For investors, STAAR represents a specialised medtech business tied less to broad healthcare utilisation and more to the long-term growth of elective refractive surgery.